Kim Roos

Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

P. Laneuville, N. Berinstein, D. Stewart, 2020 .